ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

The Impact of Calcineurin Inhibitors on De Novo DSA in Primary Kidney Transplantation

T. Hiramitsu, T. Tomosugi, K. Futamura, M. Okada, M. Tsujita, T. Ichimori, N. Goto, S. Narumi, Y. Watarai

Nagoya Daini Red Cross Hospital, Nagoya Aichi, Japan

Meeting: 2019 American Transplant Congress

Abstract number: A199

Keywords: Antibodies, Calcineurin, Immunosuppression, Kidney transplantation

Session Information

Session Name: Poster Session A: Kidney Chronic Antibody Mediated Rejection

Session Type: Poster Session

Date: Saturday, June 1, 2019

Session Time: 5:30pm-7:30pm

 Presentation Time: 5:30pm-7:30pm

Location: Hall C & D

*Purpose: De novo DSA was demonstrated as a cause of chronic AMR, leading to worse graft survival. New strategies to treat chronic AMR have been introduced. However the efficacy is still controversial. For the long graft survival, prevention of de novo DSA is important. We investigated the risk factors of de novo DSA and appropriate management of immunosuppression against de novo DSA.

*Methods: Between January 2008 and December 2016, 807 living donor kidney transplantations were performed. 652 of 807 recipients were included in this study. The risk factors for the de novo DSA were investigated in 652 recipients with multivariate analysis. 415 of 652 recipients whose immunosuppressant protocols were continued without any change after operation were investigated. In 47 of 415 recipients, de novo DSA were identified (de novo DSA positive group). By comparing between de novo DSA positive and negative groups, the appropriate management of immunosuppression was investigated.

*Results: The risk factors of de novo DSA were recipient gender, donor gender, and calcineurin inhibitor withdrawal in the multivariate analysis. The difference in the occurrence of de novo DSA among immunosuppressant protocols was not identified.

 border=

However, in the tacrolimus (TAC) and extended-release tacrolimus (TACER) based protocol, significant differences were identified in the trough levels (C0) in TAC and TACER for de novo DSA.

 border=

 border=

*Conclusions: Calcineurin inhibitors are important to prevent de novo DSA.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Hiramitsu T, Tomosugi T, Futamura K, Okada M, Tsujita M, Ichimori T, Goto N, Narumi S, Watarai Y. The Impact of Calcineurin Inhibitors on De Novo DSA in Primary Kidney Transplantation [abstract]. Am J Transplant. 2019; 19 (suppl 3). https://atcmeetingabstracts.com/abstract/the-impact-of-calcineurin-inhibitors-on-de-novo-dsa-in-primary-kidney-transplantation/. Accessed June 1, 2025.

« Back to 2019 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences